Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BERGEN BRUNSWIG ACQUIRING OWENS & MINOR's DRUG WHOLESALING BUSINESS, with annual sales volume of approximately $300 mil., in a definitive agreement announced by the two distributors on Jan. 17. The transaction involves the net assets and business of Owens & Minor's 110-year-old drug wholesale operations in Richmond and Norfolk, Va. and Wilson, N.C. but not the combination drug/medical and surgical distribution center in Ft. Lauderdale, Fla. Exact terms of the acquisition were not disclosed but Owens & Minor said the "transaction consideration will approximate $50 mil." The deal is expected to close on Feb. 29, 1992. Through the first three quarters of 1991, Owens & Minor's wholesale drug segment generated $216 mil., or 22.3%, of total sales and $2.7 mil., or 11.1%, of total operating profit. Like Bergen, Owens & Minor has a big hospital business. Owens & Minor's hospital sales account for more than half of the company's drug distribution revenues. Sales to independent community pharmacies represent about a third of the total and chains generate about 10% of Owens & Minor's pharmaceutical sales. At Orange, Calif.-based Bergen Brunswig, hospital accounts generate about 43% of drug distribution sales, independents 36% and chains 21%. The agreement does not include Owens & Minor's Glasgow, Ky.- based drug repackaging subsidiary Vangard. Nor does the deal affect the Richmond-based firm's medical/surgical distribution business. Bergen Brunswig President Robert Martini said the acquisition will allow his firm to expand its "service areas from Virginia into the mid-Atlantic states" and will benefit Bergen's health professional customers through "strengthened distribution efficiencies." Bergen Brunswig is the nation's second largest drug wholesaler with annual healthcare sales of more than $4.3 bil. in the fiscal year ended Aug. 31, 1991. Owens & Minor President & CEO G. Gilmer Minor explained that the sale will enable his firm "to clearly focus on expanding our leadership position in the medical/surgical distribution business." Minor noted that his firm's "medical/surgical business has been the largest segment and primary source of company growth and profits." Through nine months of 1991, the med/surg segment generated sales of $747.2 mil. and operating profits of $21.4 mil. Minor predicted that the enhanced focus on the medical/surgical business and the "increased financial flexibility" provided by the sale "will allow us to accelerate our growth in the medical/surgical sector and enhance our customer service quality and cost efficiency." The transaction is subject to Federal Trade Commission review before the closing date. Drug wholesaler mergers have attracted federal anti-trust attention in the past. In 1988, the Justice Department blocked McKesson's attempt to acquire Alco, and Bergen's purchase of Synergex in 1985 prompted a Justice Department review.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts